日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q

FOXM1下调是1q多发性骨髓瘤细胞中isatuximab诱导直接细胞死亡的触发因素。

Kikuchi, Jiro; Osada, Naoki; Matsuoka, Sae; Ohta, Tomomi; Kazama, Hirotaka; Shirai, Heigoro; Meloni, Marco; Chiron, Marielle; Yasui, Hiroshi; Nakasone, Hideki; Furukawa, Yusuke

c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment.

c-FOS 赋予骨髓微环境中的多发性骨髓瘤细胞干细胞样特征

Osada Naoki, Kikuchi Jiro, Matsuoka Sae, Yasui Hiroshi, Ikeda Sho, Takahashi Naoto, Furukawa Yusuke, Nakasone Hideki

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)().

发现一种新型 NSD2 抑制剂,用于治疗伴有 t(4;14) 的多发性骨髓瘤。

Matsuoka Sae, Osada Naoki, Kubota Hirokazu, Kikuzato Ko, Koyama Hiroo, Sonoda Takeshi, Idei Akiko, Yoshida Minoru, Kikuchi Masaki, Umehara Takashi, Watanabe Chiduru, Honma Teruki, Yasui Hiroshi, Ikeda Sho, Takahashi Naoto, Nakasone Hideki, Kikuchi Jiro, Furukawa Yusuke

Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells

可溶性SLAMF7是由多发性骨髓瘤细胞中的选择性剪接产生的。

Kikuchi, Jiro; Hori, Mitsuo; Osada, Naoki; Matsuoka, Sae; Suzuki, Atsushi; Kakugawa, Satoshi; Yasui, Hiroshi; Harada, Takeshi; Tenshin, Hirofumi; Abe, Masahiro; Nakasone, Hideki; Furukawa, Yusuke

Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma

对于符合移植条件的初诊多发性骨髓瘤患者,达雷妥尤单抗作为一线治疗方案具有成本效益。

Yamamoto, Chihiro; Minakata, Daisuke; Koyama, Shunsuke; Sekiguchi, Kaoru; Fukui, Yuta; Murahashi, Rui; Nakashima, Hirotomo; Matsuoka, Sae; Ikeda, Takashi; Kawaguchi, Shin-Ichiro; Toda, Yumiko; Ito, Shoko; Nagayama, Takashi; Umino, Kento; Nakano, Hirofumi; Morita, Kaoru; Yamasaki, Ryoko; Ashizawa, Masahiro; Ueda, Masuzu; Hatano, Kaoru; Sato, Kazuya; Ohmine, Ken; Fujiwara, Shin-Ichiro; Kanda, Yoshinobu